Alteogen Overview
- Year Founded
-
2008
- Status
-
Public
- Employees
-
157
- Stock Symbol
-
196170
- Investments
-
4
- Share Price
-
$127.90
- (As of Wednesday Closing)
Alteogen General Information
Description
Alteogen Inc Inc is engaged in the development and manufacture of next-generation biopharmaceuticals using NexP Fusion Technology. It also develops & markets biobetters and biosimilars through partnerships with pharmaceutical companies. It focuses on areas such as biobetters, a proprietary antibody-drug conjugate, and antibody biosimilars with complexity.
Contact Information
Website
www.alteogen.comCorporate Office
- 62, Yuseong-daero 1628beon-gil, Yuseong-gu
- Yuseong
- Daejeon, 34054
- South Korea
Corporate Office
- 62, Yuseong-daero 1628beon-gil, Yuseong-gu
- Yuseong
- Daejeon, 34054
- South Korea
Alteogen Stock Performance
As of 18-Nov-2026, Alteogen’s stock price is $127.90. Its current market cap is $8.89B with 69.5M shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $127.90 | $129.48 | $111.66 - $297.06 | $8.89B | 69.5M | 472K | $1.90 |
Alteogen Financials Summary
As of 30-Jun-2026, Alteogen has a trailing 12-month revenue of $175M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 12,251,818 | 16,463,789 | 11,052,558 | 3,850,198 |
| Revenue | 175,030 | 151,678 | 75,382 | 73,825 |
| EBITDA | 151,568 | 118,039 | 23,686 | (3,634) |
| Net Income | 132,092 | 99,545 | 45,625 | (2,579) |
| Total Assets | 479,525 | 485,235 | 277,678 | 198,731 |
| Total Debt | 4,543 | 4,902 | 7,983 | 1,323 |
Alteogen Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Alteogen Comparisons
Industry
Financing
Details
Alteogen Competitors (1)
One of Alteogen’s competitors is Halozyme Therapeutics, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Halozyme Therapeutics | Formerly VC-backed | San Diego, CA |
Alteogen Patents
Alteogen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026142345-A1 | Stable liquid formulation of fusion protein having igg fc domain | Pending | 24-Dec-2024 | ||
| WO-2026071755-A1 | Use of subcutaneous injection formulation comprising hyaluronidase used in combination with antibody-drug conjugate, and method for treating disease by using same | Pending | 25-Sep-2024 | ||
| WO-2025249934-A1 | Pharmaceutical composition for subcutaneous injection, comprising growth hormone receptor antagonist and long-acting carrier | Pending | 29-May-2024 | ||
| WO-2024248231-A1 | Method for producing long-acting hormone receptor antagonists | Inactive | 01-Jun-2023 | ||
| EP-4685232-A1 | Novel hyaluronidase variants and pharmaceutical composition comprising same | Pending | 23-Mar-2023 | C12N9/2434 |
Alteogen Signals
Alteogen Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Alteogen Investments & Acquisitions (4)
Alteogen’s most recent deal was a Early Stage VC with Thor Therapeutics. The deal was made on 30-Oct-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Thor Therapeutics | 30-Oct-2026 | Early Stage VC | Drug Discovery | ||
| Altos Biologics | 06-Oct-2026 | Secondary Transaction - Private | Biotechnology | ||
| Altos Biologics | 22-May-2025 | Merger/Acquisition | Biotechnology | ||
| GS Platech (13198.13 Square Meters Land and Building in Daejeon, South Korea) | 31-Mar-2015 | Corporate Asset Purchase | Buildings and Property |
Alteogen ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
33.53 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Alteogen FAQs
-
When was Alteogen founded?
Alteogen was founded in 2008.
-
Where is Alteogen headquartered?
Alteogen is headquartered in Daejeon, South Korea.
-
What is the size of Alteogen?
Alteogen has 157 total employees.
-
What industry is Alteogen in?
Alteogen’s primary industry is Drug Discovery.
-
Is Alteogen a private or public company?
Alteogen is a Public company.
-
What is Alteogen’s stock symbol?
The ticker symbol for Alteogen is 196170.
-
What is the current stock price of Alteogen?
As of 18-Nov-2026 the stock price of Alteogen is $127.90.
-
What is the current market cap of Alteogen?
The current market capitalization of Alteogen is $8.89B.
-
What is Alteogen’s current revenue?
The trailing twelve month revenue for Alteogen is $175M.
-
Who are Alteogen’s competitors?
Halozyme Therapeutics is a competitor of Alteogen.
-
What is Alteogen’s annual earnings per share (EPS)?
Alteogen’s EPS for 12 months was $1.90.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process